This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Annexin Pharmaceuticals Valuation

Is ANNX BTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ANNX BTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ANNX BTA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANNX BTA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANNX BTA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ANNX BTA. This is calculated by dividing ANNX BTA's market cap by their current preferred multiple.
What is ANNX BTA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

ANNX BTA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-3.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ANNX BTA's PB Ratio compare to its peers?

The above table shows the PB ratio for ANNX BTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	22.2x
CESSA Cessatech	15.3x	n/a	DKK 237.0m
PILA Pila Pharma	49.7x	n/a	SEK 128.0m
ALZCUR AlzeCure Pharma	3.4x	67.2%	SEK 135.1m
ODI ODI Pharma	20.6x	n/a	SEK 45.7m
ANNX BTA Annexin Pharmaceuticals	24.7x	46.9%	SEK 156.7m

Price-To-Book vs Peers: ANNX BTA is expensive based on its Price-To-Book Ratio (24.7x) compared to the peer average (12.7x).

Price to Earnings Ratio vs Industry

How does ANNX BTA's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	73.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	73.2%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: ANNX BTA is expensive based on its Price-To-Book Ratio (24.7x) compared to the Swedish Pharmaceuticals industry average (4.9x).

Price to Book Ratio vs Fair Ratio

What is ANNX BTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANNX BTA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	24.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ANNX BTA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.